RADX vs RNAZ vs ARWR vs RNW

For growth investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus 19. 4% for ReNew Energy Global Plc (RNW). ReNew Energy Global Plc (RNW) offers the better valuation at 46. 9x trailing P/E (0. 4x forward), making it the more compelling value choice. Analysts rate Arrowhead Pharmaceuticals, Inc. (ARWR) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arrowhead Pharmaceuticals, Inc.

(ARWR) delivered a total return of +17. 4%, compared to -100. 0% for TransCode Therapeutics, Inc. (RNAZ). Over 10 years, the gap is even starker: ARWR returned +1253% versus RNAZ's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ReNew Energy Global Plc (RNW) is the lower-risk stock at 0.

62β versus Arrowhead Pharmaceuticals, Inc. 's 1. 81β — meaning ARWR is approximately 191% more volatile than RNW relative to the S&P 500. On balance sheet safety, Arrowhead Pharmaceuticals, Inc. (ARWR) carries a lower debt/equity ratio of 73% versus 6% for ReNew Energy Global Plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.

(ARWR) is pulling ahead at 232. 6% versus 19. 4% for ReNew Energy Global Plc (RNW). On earnings-per-share growth, the picture is similar: Arrowhead Pharmaceuticals, Inc. grew EPS 99. 8% year-over-year, compared to 10. 1% for ReNew Energy Global Plc. Over a 3-year CAGR, RADX leads at 643. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ReNew Energy Global Plc (RNW) is the more profitable company, earning 3.

9% net margin versus -1055. 3% for Radiopharm Theranostics Limited — meaning it keeps 3. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNW leads at 53. 5% versus -1050. 6% for RADX. At the gross margin level — before operating expenses — ARWR leads at 97. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RNW: 20.

7% to $6. 52.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ReNew Energy Global Plc (RNW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

62)). Both have compounded well over 10 years (RNW: -50. 5%, RNAZ: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RADX (Healthcare) and RNAZ (Healthcare) and ARWR (Healthcare) and RNW (Utilities)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RADX is a small-cap high-growth stock; RNAZ is a small-cap quality compounder stock; ARWR is a mid-cap high-growth stock; RNW is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.